The Investigational Cancer Therapeutics Fellowship provides an exemplary training experience for fellows who wish to become experts in personalized cancer therapies and novel drug development, and prepare fellows for careers as the next generation of independent clinical researchers.
The fellowship offers a one-, two-, or three-year experience in early drug development. Fellows are trained in developing and conducting innovative clinical/translational trials with novel, targeted agents and are prepared for careers in academics, the pharmaceutical industry or government.
MD Anderson provides a rich experience for fellows. Over 120,000 patients were seen here last year, and nearly one-third were new patients. Almost 7,600 participants were enrolled in clinical trials exploring innovative treatments. In FY2013, our department alone had over 122 therapeutic trials and enrolled over 1,000 patients on our protocols. About one-fourth of our phase I trials are first-in-human studies.
There is a wealth of opportunity for interactions with a wide variety of investigators who are internationally known for their expertise in basic, translational and/or clinical science. Fellows will learn how to write trials, interact with sponsors, develop translational endpoints to understand drug impact and factors predicting response and host toxicity, present data at national or international meetings, analyze data and write/complete manuscripts.
Program applicants should have:
- M.D. or D.O. degree
- Completed an hematology/oncology residency or equivalent training
- An interest in a career in drug development
- Passed the licensure exam (USMLE Steps 1 & 2)
- Foreign-trained applicants must have ECFMG certification
Although completion of medical oncology training is not a requirement, fellows who have completed this training will be highly competitive for a fellowship position.
The Fellowship is supported by the Jeanne F. Shelby Scholarship Fund for Investigational Cancer Therapeutics.
Conferences & Courses
- Investigational Cancer Therapeutics Grand Rounds
- Clinical Trials Treatment Planning Meeting
- Journal Club
- Ethics in Clinical Trials Research (GS21 1102)
- Translational Sciences: From Bedside to Bench and Back (GS21 1232)
- Seminars in Clinical Cancer Research (GS21 1011)
- Seminars in Clinical Cancer Treatment (GS21 1031)
- Human Protocol Research (GS21 1132)
- Translational Cancer Research (GS21 1613)
- Resources and Methods for Analysis of Patient-Derived Samples (GS21 1121)
Administrative Assistant to:
Sarina Piha-Paul, M.D.
Department of Investigational Cancer Therapeutics
1515 Holcombe Blvd, Unit 455
Houston, TX 77030
MD Anderson Cancer Center is committed to encouraging good health and staying true to our mission to end cancer. If you are applying for a GME fellowship or residency program starting on or after July 1, 2016, please be advised that MD Anderson will have instituted a tobacco-free hiring process as part of its efforts to achieve these goals. If you are offered an appointment, you will be subject to a Pre-Employment Drug Screen for tobacco compounds in compliance with applicable state laws. If you do not pass the urine drug screening which includes testing for tobacco compounds, you CANNOT be appointed at MD Anderson. Should you fail to meet this contingency, MD Anderson will withdraw your offer of appointment for the academic year. You may reapply for the following academic year, but there are no guarantees that you will be offered a position as many of our programs are already filled for several years out.